Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: Focus on clinical application of verteporfin photodynamic therapy

British Journal of Ophthalmology

Volumn 85, Issue 4, 2001, Pages 483-495

  Soubrane, G ^a   Bressler, N M ^b  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

DISEASE ASSOCIATION; LASER COAGULATION; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; VISION; VISUAL ACUITY;

AGED; ANIMALS; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIALS; HAPLORHINI; HUMANS; LASER COAGULATION; MACULAR DEGENERATION; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROGNOSIS; RABBITS; RECURRENCE; TREATMENT OUTCOME;

EID: 0035063982     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.85.4.483     Document Type: Review

References (124)

1. An international classification and grading system for age-related maculopathy and age-related macular degeneration
2. Pathogenesis of disciform detachment of the neuroepithelium. III. Senile disciform macular degeneration
3. Epidemiology of RPE disease
4. Bilateral macular drusen in age-related macular degeneration. Prognosis and risk factors
5. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials
6. Age-related macular degeneration histopathologic studies. The 1992 Lorenz E Zimmerman Lecture
7. Senile macular degeneration: A histopathologic study
8. Age-related macular degeneration and blindness due to neovascular maculopathy
9. Age-related macular degeneration
10. The Framingham Eye Study. I. Outline and major prevalence findings
11. The grading and prevalence of macular degeneration in Chesapeake Bay watermen
12. Prevalence of age-related maculopathy. The Beaver Dam Eye Study
13. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study
14. The prevalence of age-related maculopathy in the Rotterdam Study
15. The dimensions of the problem of eye disease among the elderly
16. Is the incidence of registrable age-related macular degeneration increasing?
17. Age-related macular degeneration and choroidal neovascularization
18. The impact of macular photocoagulation study results on the treatment of exudative age-related macular degeneration
19. Clinical characteristics of choroidal neovascular membranes
20. Subretinal neovascularization in senile macular degeneration
21. Experimental therapies for age-related macular degeneration
22. Age-related macular degeneration: A review of experimental treatments
23. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration
24. Photocoagulation des neovaisseaux sous-retiniens dans la degenerescence maculaire senile par laser a argon: Resultats de l'etude randomisee de 60 cas
25. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials
26. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials
27. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity
28. Perifoveal laser treatment for subfoveal choroidal new vessels in age-related macular degeneration. Results of a randomized clinical trial
29. Senile disciform macular degeneration: Features indicating suitability for photocoagulation
30. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin One-year results of 2 randomized clinical trials - TAP Report 1
31. Photodynamic therapy
32. Photodynamic therapy of exudative age-related macular degeneration
33. Role of neovasculature and vascular permeability on the tumor retention of photodynamic agents
34. Mechanisms of tumor necrosis induced by photodynamic therapy
35. Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization
36. Photodynamic therapy in ocular vascular disease
37. Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring A (BPD-MA)
38. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative
39. Photodynamic therapy (PDT) of experimental choroidal neovascularization (CNV) using benzoporphyrin derivative (BPD-MA): Dye delivery and treatment parameters
40. Differences in the uptake of modified low density lipoproteins by tissue cultured endothelial cells
41. Lipoprotein receptors and endothelial cells
42. Imaging of experimental choroidal neovascularization (CNV) using liposomal benzoporphyrin derivative mono-acid (BPD-MA) angiography
43. Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin
44. In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization
45. Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye
46. Liposomal benzoporphyrin derivative verteporfin in photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys
47. Photodynamic therapy of experimental intraocular melanoma using benzoporphyrin lipoprotein
48. Photosensitising potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumour model
49. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin
50. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment
51. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey
52. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration. Results of a single treatment in a phase 1 and 2 study
53. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration. Results of retreatments in a phase 1 and 2 study
54. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angoid streaks, and idiopathic causes
55. Indocyanine green-guided laser photocoagulation of focal spots at the edge of plaques of choroidal neovascularization
56. Indocyanine green angiography-guided photocoagulation of choroidal neovascularization associated with retinal pigment epithelial detachment
57. Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration
58. Indocyanine green dye-enhanced diode laser photocoagulation of poorly defined subfoveal choroidal neovascularisation
59. Laser treatment of feeder vessels in subfoveal choroidal neovascular membranes. A revisitation using dynamic indocyanine green angiography
60. Feeder vessel photocoagulation of subfoveal choroidal neovascularization secondary to age-related macular degeneration
61. Response of the retinal pigment epithelium to selective photocoagulation
62. Subthreshold (retinal pigment epithelium) photocoagulation in macular diseases: A pilot study
63. Transpupillary thermotherapy for choroidal melanoma. Tumor control and visual results in 100 consecutive cases
64. Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration
65. Submacular surgery. Are randomized trials necessary?
66. Submacular surgery for age-related macular degeneration
67. Surgical management of subfoveal choroidal neovascularization
68. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes
69. Clinicopathologic correlations of surgically excised type I and type 2 submacular choroidal neovascular membranes
70. Surgical removal of subfoveal choroidal neovascularization in age-related macular degeneration
71. Subfoveal choroidal neovascularization: Is there a role for submacular surgery?
72. Tissue plasminogen activator-assisted surgical excision of subfoveal choroidal neovascularization in age-related macular degeneration. A randomized double-masked trial
73. Visual results after surgical removal of subfoveal choroidal neovascular membranes
74. Retinal separation, retinotomy, and macular relocation: II. A surgical approach for age-related macular degeneration?
75. Macular translocation for surgical management of subfoveal choroidal neovascularizations in patients with AMD: First results
76. Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration
77. Translocation of the retina for management of subfoveal choroidal neovascularization II: A preliminary report in humans
78. Retinal pigment epithelium translocation after choroidal neovascular membrane removal in age-related macular degeneration
79. Immunological problems of transplantation into the subretinal space
80. Transplantation of cultured human retinal cells to monkey retina
81. The first decade of continuous progress in retinal transplantation
82. Heterologous iris pigment epithelium transplantation in a rabbit model
83. The transplantation of human fetal neuroretinal cells in advanced retinitis pigmentosa patients: Results of a long-term safety study
84. Normal retina releases a diffusible factor stimulating cone survival in the retinal degeneration mouse
85. Subretinal electrical stimulation of the rabbit retina
86. Subretinal semiconductor microphotodiode array
87. The development of subretinal microphotodiodes for replacement of degenerated photoreceptors
88. Pattern electrical stimulation of the human retina
89. Visual perception elicited by electrical stimulation of retina in blind humans
90. Radiation therapy for age-related macular degeneration
91. 1996 Jules Gonin lecture of the Retina Research Foundation. Long-term results after proton irradiation of uveal melanomas
92. Treatment of age-related subfoveal neovascular membranes by teletherapy: A pilot study
93. External beam radiotherapy (20 Gy, 2 Gy fractions) fails to control the growth of choroidal neovascularization in age-related macular degeneration: A review of III cases
94. External beam radiation therapy for choroidal neovascularization
95. Radiotherapy for choroidal neovascularization in age-related macular degeneration. A pilot study using low-versus high-dose photon beam radiation
96. Radiotherapy for isolated occult subfoveal neovascularisation in age related macular degeneration: A pilot study
97. A prospective, randomized, double-blind trial on radiation therapy for neovascular age-related macular degeneration (RAD Study)
98. A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: Radiation versus observation
99. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial
100. Thalidomide is an inhibitor of angiogenesis
101. Evidence that AL-3789 inhibits retinal neovascularization in an animal model of ROP by inducing retinal PAI-1
102. Efficacy of AG3340, a selective inhibitor of matrix metalloproteases in an animal model of retinal neovascularization
103. The apoptosis protein p53 could be detected in human microvascular endothelial cells treated by genistein
104. Inhibition of retinal neovascularization by a broad spectrum matrix metalloproteinase inhibitor in an animal model of ROP
105. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization
106. Thalidomide and neovascular age-related macular degeneration (NVARMD)
107. Growth factors in age-related macular degeneration: Pathogenic and therapeutic implications
108. Vascular endothelial growth factor and the eye: Biochemical mechanisms of action and implications for novel therapies
109. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor
110. Expression of vascular endothelial growth factor and its receptor (KDR/flk-1) mRNA in experimental choroidal neovascularization
111. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: One-year results of a randomized clinical trial-VIP Report No 1
112. In vivo photodynamic therapy with the new near-IR absorbing water soluble photosensitizer lutetium texaphyrin and a high intensity pulsed light delivery system
113. Digital angiography using lutetium texaphyrin in a monkey model of choroidal neovascularization
114. Photodynamic therapy of corneal neovascularization using tin ethyl etiopurpurin (SnET2)
115. Purlytin (SnET2)-photodynamic therapy produces closure of subfoveal choroidal neovascularization in humans
116. Visual acuity stabilizes after a single treatment with SnET2 photodynamic therapy in patients with subfoveal choroidal neovascularization
117. Mono-L-aspartyl chlorin e6 (NPe6) angiography of the retina in pigmented rats, rabbits, and monkeys
118. Mono-L-aspartyl chlorin e6 (Npe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model
119. The Age-Related Eye Disease Study (AREDS): Design implications. AREDS report no 1
120. The Age-Related Eye Disease Study (AREDS): A clinical trial of zinc and antioxidants. AREDS study report no. 2
121. Laser treatment in eyes with drusen